Robbie Williams has expressed concern that his weight-loss injections may be negatively affecting his eyesight. The 51-year-old singer, known for his time with the band Take That, reported that his vision has become increasingly blurry in recent months, leading him to suspect that the medication could be the cause.
During an interview with The Sun, Williams explained that he first noticed a problem while watching an American football game, where he could only see players as “just shapes on the field.” Although an optician prescribed new glasses, he did not initially connect his eyesight issues to the weight-loss injections. The situation has become more pronounced during his performances, particularly during a moment in his song She’s The One, where he interacts directly with audience members. He admitted that he struggles to see the faces in front of him, saying, “They’re having this incredible moment, and little do they know I can’t see them.”
Williams has been using Mounjaro, a medication that mimics the hormone GLP-1 to control appetite and assist with weight management. Following his use of the drug, he has lost weight, dropping from 13 stone 13 pounds to 12 stone 1 pound. He has previously discussed how fluctuations in his weight affect his mental health, describing his inner critic as “maddening” when he gains weight.
While Williams has benefitted from Mounjaro in terms of mental health, describing the effects as “transformative,” he is now concerned about the rapid decline in his vision. He believes the changes are too abrupt to be simply attributed to age. His experience comes at a time when research from the United States suggests there may be a link between drugs based on Semaglutide, like Mounjaro, and a rare optic nerve condition that can lead to blindness.
Researchers remain divided on the issue, but reports of vision-related side effects have surfaced in the United Kingdom, raising alarms among users and medical professionals alike. The growing number of cases has prompted discussions about the safety and potential risks associated with these weight-loss medications.
Despite his concerns, Williams continues to advocate for awareness regarding possible side effects of weight-loss injections. He hopes that sharing his experience will encourage others to consider the implications of such treatments. As the landscape of weight management evolves, it is crucial for users to stay informed about the potential risks and benefits associated with these medications.
